Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake
Ticker: PRCWF · Form: SC 13D/A · Filed: Sep 4, 2024 · CIK: 1863362
Sentiment: neutral
Topics: schedule-13d, amendment, ownership-filing
TL;DR
Hoche Partners Pharma Holding S.A. updated its 13D filing for Procaps Group, S.A. on 9/4/2024.
AI Summary
Hoche Partners Pharma Holding S.A. filed an amendment (No. 8) to its Schedule 13D on September 4, 2024, regarding its holdings in Procaps Group, S.A. The filing indicates a change in the reporting person's ownership or control of the subject company's ordinary shares.
Why It Matters
This filing signals a potential shift in the ownership structure or strategic intentions of a significant shareholder in Procaps Group, S.A., which could impact the company's stock price and future direction.
Risk Assessment
Risk Level: medium — Amendments to Schedule 13D filings often indicate changes in a significant shareholder's intentions or holdings, which can introduce uncertainty and volatility.
Key Players & Entities
- Hoche Partners Pharma Holding S.A. (company) — Reporting person filing the Schedule 13D/A
- Procaps Group, S.A. (company) — Subject company
- September 4, 2024 (date) — Date of the event requiring the filing
FAQ
What is the CUSIP number for Procaps Group, S.A. ordinary shares?
The CUSIP number for Procaps Group, S.A. ordinary shares is L7756P 102.
Who is the subject company in this filing?
The subject company is Procaps Group, S.A.
What form is being filed?
A Schedule 13D/A (Amendment No. 8) is being filed.
When was the date of the event requiring this filing?
The date of the event requiring this filing was September 4, 2024.
What is the principal executive office address for Procaps Group, S.A.?
The principal executive office address is 9 rue de Bitbourg, L-1273 Luxembourg Grand Duchy of Luxembourg.
Filing Stats: 1,500 words · 6 min read · ~5 pages · Grade level 10.8 · Accepted 2024-09-04 20:50:49
Key Financial Figures
- $0.01 — er) Ordinary Shares, nominal value of $0.01 per share (Title of Class of Securiti
- $77 million — the Company projected generating about $77 million to $82 million in EBITDA in fiscal year
- $82 million — ojected generating about $77 million to $82 million in EBITDA in fiscal year 2023 (already
- $17 million — fforts” with a negative impact of $17 million (!) on its EBITDA. The increase of the
Filing Documents
- procaps_13da8.htm (SC 13D/A) — 43KB
- ex99_17.htm (EX-99.17) — 10KB
- 0001019056-24-000274.txt ( ) — 54KB
of the Schedule 13D
Item 7 of the Schedule 13D is hereby amended by adding the following: Exhibit 99.16 — Press release issued by Procaps Group, S.A., dated September 03, 2024 incorporated herein by reference to the Form 6-K filed by Procaps Group, S.A. with the Securities and Exchange Commission on September 03, 2024. Exhibit 99.17 — Letter from Alejandro Weinstein to the Board of Directors of Procaps Group, S.A. dated September 03, 2024. SIGNATURE After reasonable inquiry and to the best of the Reporting Person’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: September 04, 2024 hoche partners pharma holding s.a. By: /s/ Roman Sokolowski Name: Roman Sokolowski Title: Director Stonehage Fleming Corporate Service Luxembourg S.A., Director By: /s/ Alexander Ludbrook - Miles Name: Alexander Ludbrook - Miles Title: Director By: /s/ Ariane Vansimpsen Name: Ariane Vansimpsen Title: Director